Abstract
In case-control profiling studies, increasing the sample size does not always improve statistical power because the variance may also be increased if samples are highly heterogeneous. For instance, tumor samples used for gene expression assay are often heterogeneous in terms of tissue composition or mechanism of progression, or both; however, such variation is rarely taken into account in expression profiles analysis. We use a prostate cancer prognosis study as an example to demonstrate that solely recruiting more patient samples may not increase power for biomarker detection at all. In response to the heterogeneity due to mixed tissue, we developed a sample selection strategy termed Stepwise Enrichment by which samples are systematically culled based on tumor content and analyzed with t-test to determine an optimal threshold for tissue percentage. The selected tissue-percentage threshold identified the most significant data by balancing the sample size and the sample homogeneity; therefore, the power is substantially increased for identifying the prognostic biomarkers in prostate tumor epithelium cells as well as in prostate stroma cells. This strategy can be generally applied to profiling studies where the level of sample heterogeneity can be measured or estimated.
Keywords: Expression profiles, Cell-type heterogeneity, Prostate cancer, Statistical power, Sample size, Stepwise enrichment
Anti-Cancer Agents in Medicinal Chemistry
Title:A Sample Selection Strategy to Boost the Statistical Power of Signature Detection in Cancer Expression Profile Studies
Volume: 13 Issue: 2
Author(s): Zhenyu Jia, Yipeng Wang, Yuanjie Hu, Christine McLaren, Yingyan Yu, Kai Ye, Xiao-Qin Xia, James A. Koziol, Waldemar Lernhardt, Michael McClelland and Dan Mercola
Affiliation:
Keywords: Expression profiles, Cell-type heterogeneity, Prostate cancer, Statistical power, Sample size, Stepwise enrichment
Abstract: In case-control profiling studies, increasing the sample size does not always improve statistical power because the variance may also be increased if samples are highly heterogeneous. For instance, tumor samples used for gene expression assay are often heterogeneous in terms of tissue composition or mechanism of progression, or both; however, such variation is rarely taken into account in expression profiles analysis. We use a prostate cancer prognosis study as an example to demonstrate that solely recruiting more patient samples may not increase power for biomarker detection at all. In response to the heterogeneity due to mixed tissue, we developed a sample selection strategy termed Stepwise Enrichment by which samples are systematically culled based on tumor content and analyzed with t-test to determine an optimal threshold for tissue percentage. The selected tissue-percentage threshold identified the most significant data by balancing the sample size and the sample homogeneity; therefore, the power is substantially increased for identifying the prognostic biomarkers in prostate tumor epithelium cells as well as in prostate stroma cells. This strategy can be generally applied to profiling studies where the level of sample heterogeneity can be measured or estimated.
Export Options
About this article
Cite this article as:
Jia Zhenyu, Wang Yipeng, Hu Yuanjie, McLaren Christine, Yu Yingyan, Ye Kai, Xia Xiao-Qin, A. Koziol James, Lernhardt Waldemar, McClelland Michael and Mercola Dan, A Sample Selection Strategy to Boost the Statistical Power of Signature Detection in Cancer Expression Profile Studies, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871520611313020004
DOI https://dx.doi.org/10.2174/1871520611313020004 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Immunomodulatory Activities of Glucocorticoids: Insights from Transgenesis and Gene Targeting
Current Pharmaceutical Design Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP
Current Pharmaceutical Analysis Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Involvement of CD24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy
Current Cancer Drug Targets Inhibition of P-Glycoprotein Mediated Efflux of Paclitaxel by Coumarin Derivatives in Cancer Stem Cells: An In Silico Approach
Combinatorial Chemistry & High Throughput Screening A Review of the Most Important Classes of Serine Protease Inhibitors in Insects and Leeches
Medicinal Chemistry Reviews - Online (Discontinued) Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Inhibition of P450 17 as a New Strategy for the Treatment of Prostate Cancer
Current Medicinal Chemistry Editorial [Hot Topic: Anti-Lipogenesis as a Novel Strategy for Cancer Therapy (Guest Editors: Jianghua Liu and Deliang Cao)]
Recent Patents on Anti-Cancer Drug Discovery Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Editorial (Thematic Issue: Crosstalk Between the Nervous and the Immune Systems in Health and Sickness)
Current Pharmaceutical Design Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry Fish Genomes, Comparative Genomics and Vertebrate Evolution
Current Genomics Structure-Activity Relationship of Nuclear Receptor-Ligand Interactions
Current Topics in Medicinal Chemistry Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy
Current Medicinal Chemistry The Concept of Dysregulated Signal Transduction and Gene Expression in the Pathophysiology of Mood Disorders
Current Psychiatry Reviews